Goldman Sachs Maintains Neutral on Tarsus Pharmaceuticals, Raises Price Target to $51
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Andrea Tan maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Neutral and raises the price target from $46 to $51.
Goldman Sachs analyst Andrea Tan maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Neutral and raises the price target from $46 to $51.